PDF(Pubmed)
Abstract：
UNASSIGNED: Hypofractionated radiotherapy in the treatment of prostate cancer has been widely studied. However, in the postoperative setting it has been less explored. The objective of this prospective study is to evaluate the safety and efficacy of hypofractionated radiotherapy in postoperative prostate cancer.
UNASSIGNED: A prospective study was designed to include patients with prostate cancer with an indication of postoperative radiotherapy as adjuvant or salvage. A hypofractionated radiotherapy scheme of 51 Gy in 17 fractions was performed with the possibility of treating the pelvis at a dose of 36 Gy in 12 fractions sequentially. Safety was evaluated based on acute and late toxicity [according to the Radiation Therapy Oncology Group (RTOG) scale and Common Terminology Criteria Adverse Events (CTCAE) v4.03], International Prognostic Scoring System (IPSS) over time, and quality of life.
UNASSIGNED: From August 2020 to June 2022, 31 patients completed treatment and were included in this report. 35.5% of patients received elective treatment of the pelvic nodal areas. Most patients reported minimal or low acute toxicity, with an acute gastrointestinal (GI) and genitourinary (GU) grade 3 or greater toxicity of 3.2% and 0%, respectively. The evolution in time of the IPSS remained without significant differences (p = 0.42). With the exception of a significant improvement in the domains of hormonal and sexual symptoms of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire, the rest of the domains [EPIC, European Organization for Research and Treatment of Cancer (EORTC) Core quality of life questionnaire (C-30) and Prostate Cancer module (PR-25)] were maintained without significant differences over time. With a follow-up of 15.4 months, late GI and GU grade 2 toxicity was reported greater than 0% and 9.6%, respectively.
UNASSIGNED: Hypofractionated radiotherapy in postoperative prostate cancer appears to be safe with low reports of relevant acute or late toxicity. Further follow-up is required to confirm these results.
UNASSIGNED: The protocol was approved by the accredited Medical Ethical Committee of Pontificia Universidad Católica de Chile. All participants accepted and wrote informed consent.
UNASSIGNED: A prospective study was designed to include patients with prostate cancer with an indication of postoperative radiotherapy as adjuvant or salvage. A hypofractionated radiotherapy scheme of 51 Gy in 17 fractions was performed with the possibility of treating the pelvis at a dose of 36 Gy in 12 fractions sequentially. Safety was evaluated based on acute and late toxicity [according to the Radiation Therapy Oncology Group (RTOG) scale and Common Terminology Criteria Adverse Events (CTCAE) v4.03], International Prognostic Scoring System (IPSS) over time, and quality of life.
UNASSIGNED: From August 2020 to June 2022, 31 patients completed treatment and were included in this report. 35.5% of patients received elective treatment of the pelvic nodal areas. Most patients reported minimal or low acute toxicity, with an acute gastrointestinal (GI) and genitourinary (GU) grade 3 or greater toxicity of 3.2% and 0%, respectively. The evolution in time of the IPSS remained without significant differences (p = 0.42). With the exception of a significant improvement in the domains of hormonal and sexual symptoms of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire, the rest of the domains [EPIC, European Organization for Research and Treatment of Cancer (EORTC) Core quality of life questionnaire (C-30) and Prostate Cancer module (PR-25)] were maintained without significant differences over time. With a follow-up of 15.4 months, late GI and GU grade 2 toxicity was reported greater than 0% and 9.6%, respectively.
UNASSIGNED: Hypofractionated radiotherapy in postoperative prostate cancer appears to be safe with low reports of relevant acute or late toxicity. Further follow-up is required to confirm these results.
UNASSIGNED: The protocol was approved by the accredited Medical Ethical Committee of Pontificia Universidad Católica de Chile. All participants accepted and wrote informed consent.
摘要：
■大分割放疗在前列腺癌治疗中的应用已被广泛研究。然而,在术后设置中，它很少被探索。这项前瞻性研究的目的是评估大分割放疗在前列腺癌术后的安全性和有效性。
■设计了一项前瞻性研究，以纳入有术后放疗指征的前列腺癌患者作为辅助或抢救。在17个部分中进行51Gy的大分割放射治疗方案，并有可能在12个部分中以36Gy的剂量依次治疗骨盆。根据急性和晚期毒性评估安全性[根据放射治疗肿瘤组（RTOG）量表和通用术语标准不良事件（CTCAE）v4.03]，随着时间的推移，国际预后评分系统(IPSS)，和生活质量。
■从2020年8月至2022年6月，31名患者完成了治疗并纳入本报告。35.5%的患者接受了盆腔淋巴结区域的选择性治疗。大多数患者报告的急性毒性最小或低，急性胃肠道（GI）和泌尿生殖系统（GU）3级或更高的毒性为3.2％和0％，分别。IPSS的时间演变没有显著差异(p=0.42)。除了扩大前列腺癌综合指数（EPIC）问卷的激素和性症状领域的显着改善外，其余领域[EPIC，欧洲癌症研究和治疗组织（EORTC）核心生活质量问卷（C-30）和前列腺癌模块（PR-25）]随着时间的推移没有显着差异。经过15.4个月的随访，晚期GI和GU2级毒性报告大于0%和9.6%，分别。
■前列腺癌术后小分割放疗似乎是安全的，相关急性或晚期毒性的报道较少。需要进一步的随访来确认这些结果。
■该协议由智利天主教大学医学伦理委员会批准。所有参与者接受并写知情同意书。
■设计了一项前瞻性研究，以纳入有术后放疗指征的前列腺癌患者作为辅助或抢救。在17个部分中进行51Gy的大分割放射治疗方案，并有可能在12个部分中以36Gy的剂量依次治疗骨盆。根据急性和晚期毒性评估安全性[根据放射治疗肿瘤组（RTOG）量表和通用术语标准不良事件（CTCAE）v4.03]，随着时间的推移，国际预后评分系统(IPSS)，和生活质量。
■从2020年8月至2022年6月，31名患者完成了治疗并纳入本报告。35.5%的患者接受了盆腔淋巴结区域的选择性治疗。大多数患者报告的急性毒性最小或低，急性胃肠道（GI）和泌尿生殖系统（GU）3级或更高的毒性为3.2％和0％，分别。IPSS的时间演变没有显著差异(p=0.42)。除了扩大前列腺癌综合指数（EPIC）问卷的激素和性症状领域的显着改善外，其余领域[EPIC，欧洲癌症研究和治疗组织（EORTC）核心生活质量问卷（C-30）和前列腺癌模块（PR-25）]随着时间的推移没有显着差异。经过15.4个月的随访，晚期GI和GU2级毒性报告大于0%和9.6%，分别。
■前列腺癌术后小分割放疗似乎是安全的，相关急性或晚期毒性的报道较少。需要进一步的随访来确认这些结果。
■该协议由智利天主教大学医学伦理委员会批准。所有参与者接受并写知情同意书。
